用于治疗埃博拉病毒感染的药物靶点和抗病毒分子

The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.

作者信息

Wu Wenjiao, Liu Shuwen

机构信息

State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University University, Guangzhou, China.

出版信息

Curr Top Med Chem. 2017;17(3):361-370. doi: 10.2174/1568026616666160829161318.

DOI:10.2174/1568026616666160829161318

PMID:27572081

Abstract

Ebola virus (EBOV) is a highly pathogenic virus causing severe hemorrhagic fever with a high case fatality rate of 50% - 90% in humans. Without an approved vaccine or treatments, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission. These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa. As with the increase of outbreaks, a significant effort has been made to develop promising countermeasures for the prevention and treatment of Ebola virus infection. In this review, development of therapeutics and potential inhibitors for Ebola virus infection will be discussed.

摘要

埃博拉病毒（EBOV）是一种高致病性病毒，可引发严重出血热，在人类中的病死率高达50% - 90%。由于缺乏获批的疫苗或治疗方法，埃博拉疫情的管控一直局限于姑息治疗和防止传播的隔离措施。然而，这些措施仍未能阻止2014年在西非长期肆虐的埃博拉疫情。随着疫情的增多，人们已付出巨大努力来开发有望预防和治疗埃博拉病毒感染的应对措施。在本综述中，将讨论埃博拉病毒感染的治疗方法和潜在抑制剂的开发情况。